ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital Miguel Servet
Zaragoza, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Miguel Servet (18)
2020
-
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2019
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
Physical activity and breast cancer risk by pathological subtype
Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
-
Quality indicators to assure and improve cancer care in Spain using the delphi technique
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558
2015
2013
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
-
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: A pooled analysis
Breast Cancer Research, Vol. 15, Núm. 6
2012
-
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
Breast Cancer Research and Treatment, Vol. 136, Núm. 2, pp. 487-493
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer
Anticancer Research, Vol. 30, Núm. 6, pp. 2255-2261
-
Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register
Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2006
-
The «El Álamo» project (1990-1997): Two consecutive hospital-based studies of breast cancer outcomes in Spain
Clinical and Translational Oncology, Vol. 8, Núm. 7, pp. 508-518
2005
-
Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)
Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27
2003
-
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer
Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291